Tuberculosis

被引：6

作者：

Lange, Christoph ^{[1
,2
,3
,4
]}

Kalsdorf, Barbara ^{[1
]}

Maurer, Florian P. ^{[6
]}

Heyckendorf, Jan ^{[1
,5
]}

机构：

[1] Forschungszentrum Borstel, Leibniz Lungenzentrum, Med Klin, Parkallee 35, D-23845 Borstel, Germany

[2] Deutsch Zentrum Infekt Forsch DZIF, TB Unit, Braunschweig, Germany

[3] Univ Lubeck, Resp Med & Int Hlth, Lubeck, Germany

[4] Karolinska Inst, Stockholm, Sweden

[5] Deutsch Zentrum Infekt Forsch DZIF, Braunschweig, Germany

[6] Forschungszentrum Borstel, Leibniz Lungenzentrum, Natl Referenzzentrum Mykobakterien, Borstel, Germany

来源：

INTERNIST | 2019年 / 60卷 / 11期

关键词：

Mycobacterium tuberculosis; Tuberculosis; multidrug-resistant; pulmonary; Tuberculosis therapy; Interferon-gamma release tests; LATENT TUBERCULOSIS; MYCOBACTERIUM-TUBERCULOSIS; RIFAPENTINE; INFECTION; RIFAMPIN;

D O I：

10.1007/s00108-019-00685-z

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Tuberculosis is a bacterial infectious disease that is usually transmitted by inhalation of droplets containing the bacteria. The World Health Organization (WHO) estimates that approximately 10 million patients were newly diagnosed with tuberculosis in 2017. Rapid diagnosis relies on a combination of imaging and microbiological, molecular, and, rarely, immunological tests. Genotypic methods enable early diagnosis and allow highly accurate prediction of drug resistance. Phenotypic (culture-based) methods are the diagnostic gold standard. Standard management of patients with pan drug-susceptible pulmonary tuberculosis includes a combination of rifampicin, isoniazid, ethambutol and pyrazinamide for 2 months followed by rifampicin and isoniazid for additional 4 months, which leads to cure rates of >80%. With individualized treatment schemes, similar cure rates can be achieved for patients with multidrug-resistant tuberculosis.

引用

页码：1155 / 1175

页数：21

共 33 条

[1] A Diagnostic Algorithm To Investigate Pyrazinamide and Ethambutol Resistance in Rifampin-Resistant Mycobacterium tuberculosis Isolates in a Low-Incidence Setting [J].

Andres, Soenke ;

Groeschel, Matthias, I ;

Hillemann, Doris ;

Merker, Matthias ;

Niemann, Stefan ;

Kranzer, Katharina .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (02)

[2]

[Anonymous], 2019, BERICHT EPIDEMIOLOGI

[3]

[Anonymous], 2018, BER EP TUB DEUTSCHL

[4] High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial [J].

Boeree, Martin J. ;

Heinrich, Norbert ;

Aarnoutse, Rob ;

Diacon, Andreas H. ;

Dawson, Rodney ;

Rehal, Sunita ;

Kibiki, Gibson S. ;

Churchyard, Gavin ;

Sanne, Ian ;

Ntinginya, Nyanda E. ;

Minja, Lilian T. ;

Hunt, Robert D. ;

Charalambous, Salome ;

Hanekom, Madeleine ;

Semvua, Hadija H. ;

Mpagama, Stellah G. ;

Manyama, Christina ;

Mtafya, Bariki ;

Reither, Klaus ;

Wallis, Robert S. ;

Venter, Amour ;

Narunsky, Kim ;

Mekota, Anka ;

Henne, Sonja ;

Colbers, Angela ;

van Balen, Georgette Plemper ;

Gillespie, Stephen H. ;

Phillips, Patrick P. J. ;

Hoelscher, Michael .

LANCET INFECTIOUS DISEASES, 2017, 17 (01) :39-49

[5] Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a TBNET/RESIST-TB consensus statement [J].

Dominguez, J. ;

Boettger, E. C. ;

Cirillo, D. ;

Cobelens, F. ;

Eisenach, K. D. ;

Gagneux, S. ;

Hillemann, D. ;

Horsburgh, R. ;

Molina-Moya, B. ;

Niemann, S. ;

Tortoli, E. ;

Whitelaw, A. ;

Lange, C. .

INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2016, 20 (01) :24-U61

[6] Tuberculosis [J].

Furin, Jennifer ;

Cox, Helen ;

Pai, Madhukar .

LANCET, 2019, 393 (10181) :1642-1656

[7] Treatment of Tuberculosis [J].

Horsburgh, C. Robert, Jr. ;

Barry, Clifton E., III ;

Lange, Christoph .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (22) :2149-2160

[8] Rapid diagnosis of pulmonary tuberculosis by combined molecular and immunological methods [J].

Jafari, Claudia ;

Olaru, Ioana D. ;

Daduna, Franziska ;

Ernst, Martin ;

Heyckendorf, Jan ;

Lange, Christoph ;

Kalsdorf, Barbara .

EUROPEAN RESPIRATORY JOURNAL, 2018, 51 (05)

[9]

Krakauer, 2019, I J T L D

[10] Management of patients with multidrug-resistant tuberculosis [J].

Lange, C. ;

Aarnoutse, R. E. ;

Alffenaar, J. W. C. ;

Bothamley, G. ;

Brinkmann, F. ;

Costa, J. ;

Chesov, D. ;

van Crevel, R. ;

Dedicoat, M. ;

Dominguez, J. ;

Duarte, R. ;

Grobbel, H. P. ;

Guenther, G. ;

Guglielmetti, L. ;

Heyckendorf, J. ;

Kay, A. W. ;

Kirakosyan, O. ;

Kirk, O. ;

Koczulla, R. A. ;

Kudriashov, G. G. ;

Kuksa, L. ;

van Leth, F. ;

Magis-Escurra, C. ;

Mandalakas, A. M. ;

Molina-Moya, B. ;

Peloquin, C. A. ;

Reimann, M. ;

Rumetshofer, R. ;

Schaaf, H. S. ;

Schon, T. ;

Tiberi, S. ;

Valda, J. ;

Yablonskii, P. K. ;

Dheda, K. .

INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2019, 23 (06) :645-662

← 1 2 3 4 →